Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer.

Anthropometrics Breast cancer Caveolin-1 Cohort Prognosis

Journal

Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 30 03 2022
revised: 09 05 2022
accepted: 23 05 2022
pubmed: 7 6 2022
medline: 7 6 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

Caveolin-1 (CAV1) is associated with cholesterol-rich membrane raft domains and is a master regulator of cell signaling and membrane transport. Here, we investigated CAV1's role in cellular compartments of breast cancer in relation to signaling pathways, clinicopathological features, and clinical outcomes. CAV1 levels were evaluated with immunohistochemistry in cytoplasm of invasive tumor cells and stromal cells in tumor tissue microarrays from a cohort of 1018 breast cancer patients (inclusion 2002-2012, Sweden). Cytoplasmic and stromal CAV1 were categorized as positive/negative and strong/not strong, respectively. CAV1 expression in relation to clinical outcomes was assessed with Cox regression. Investigations into CAV1 functional pathways was conducted in the STRING, GOBO, and TCGA databases. CAV1 expression was associated with non-luminal subtypes, cell cycle control, inflammation, epithelial-mesenchymal transition, and the IGF/Insulin system. Generally, CAV1 was not associated with recurrence risk. Stromal CAV1's impact on recurrence risk was modified by BMI ≥25 kg/m CAV1's prognostic impact depended on its localization, anthropometric, and tumor factors. Stromal CAV1 predicted high recurrence risk in a group of supposedly 'low-risk' patients. Cytoplasmic CAV1 predicted metachronous contralateral disease. If confirmed, CAV1 could be used as treatment target and for risk-stratification.

Sections du résumé

BACKGROUND BACKGROUND
Caveolin-1 (CAV1) is associated with cholesterol-rich membrane raft domains and is a master regulator of cell signaling and membrane transport. Here, we investigated CAV1's role in cellular compartments of breast cancer in relation to signaling pathways, clinicopathological features, and clinical outcomes.
METHODS METHODS
CAV1 levels were evaluated with immunohistochemistry in cytoplasm of invasive tumor cells and stromal cells in tumor tissue microarrays from a cohort of 1018 breast cancer patients (inclusion 2002-2012, Sweden). Cytoplasmic and stromal CAV1 were categorized as positive/negative and strong/not strong, respectively. CAV1 expression in relation to clinical outcomes was assessed with Cox regression. Investigations into CAV1 functional pathways was conducted in the STRING, GOBO, and TCGA databases.
RESULTS RESULTS
CAV1 expression was associated with non-luminal subtypes, cell cycle control, inflammation, epithelial-mesenchymal transition, and the IGF/Insulin system. Generally, CAV1 was not associated with recurrence risk. Stromal CAV1's impact on recurrence risk was modified by BMI ≥25 kg/m
CONCLUSIONS CONCLUSIONS
CAV1's prognostic impact depended on its localization, anthropometric, and tumor factors. Stromal CAV1 predicted high recurrence risk in a group of supposedly 'low-risk' patients. Cytoplasmic CAV1 predicted metachronous contralateral disease. If confirmed, CAV1 could be used as treatment target and for risk-stratification.

Identifiants

DOI: 10.1016/j.tranon.2022.101464 PMID: 35660849 PMC: PMC9166433
pubmed: 35660849
pii: S1936-5233(22)00123-1
doi: 10.1016/j.tranon.2022.101464
pmc: PMC9166433
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101464

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Breast Cancer Res Treat. 2012 Jan;131(1):1-15
pubmed: 21901387
Endocr Rev. 2008 Apr;29(2):217-33
pubmed: 18216219
Cancer Res. 2004 May 1;64(9):3037-45
pubmed: 15126339
Nat Commun. 2016 Apr 20;7:11371
pubmed: 27094744
PLoS One. 2021 Nov 11;16(11):e0258951
pubmed: 34762666
J Clin Invest. 2020 Oct 1;130(10):5074-5087
pubmed: 32870818
Cancer Biol Ther. 2009 Jun;8(11):1071-9
pubmed: 19502809
Breast Cancer Res Treat. 2019 Feb;173(3):667-677
pubmed: 30387004
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Breast Cancer Res Treat. 2014 Aug;146(3):647-55
pubmed: 25056184
Onco Targets Ther. 2017 Nov 20;10:5491-5524
pubmed: 29200866
PLoS One. 2011 Mar 21;6(3):e17911
pubmed: 21445301
Carcinogenesis. 2021 Nov 12;42(11):1314-1325
pubmed: 34606580
Cancer Metastasis Rev. 2018 Dec;37(4):577-597
pubmed: 30465162
Cancers (Basel). 2021 Jun 18;13(12):
pubmed: 34207120
Cell. 2011 Jul 8;146(1):148-63
pubmed: 21729786
Cancer Res. 2016 Dec 15;76(24):7242-7253
pubmed: 27784747
Br J Cancer. 2016 Jul 26;115(3):382-90
pubmed: 27280635
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
Mol Cancer Res. 2020 Apr;18(4):644-656
pubmed: 31900313
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Breast Cancer Res Treat. 2006 Sep;99(1):85-90
pubmed: 16541313
NPJ Breast Cancer. 2016;2:
pubmed: 28691057
Virchows Arch. 2020 Aug;477(2):317-320
pubmed: 32080761
Cancer Sci. 2020 Aug;111(8):2708-2717
pubmed: 32573845
J Biol Chem. 1999 Nov 19;274(47):33551-6
pubmed: 10559241
Clin Cancer Res. 2007 Jan 1;13(1):90-101
pubmed: 17200343
Cancer Causes Control. 2012 Aug;23(8):1307-16
pubmed: 22695757
Am J Pathol. 2009 Jun;174(6):2023-34
pubmed: 19411448
Int J Cancer. 2018 Nov 1;143(9):2092-2104
pubmed: 29524224
J Clin Oncol. 2016 Mar 20;34(9):927-35
pubmed: 26786933
J Radiat Res. 2016 Aug;57 Suppl 1:i90-i98
pubmed: 26983987
Dtsch Arztebl Int. 2010 Jan;107(4):50-6
pubmed: 20165700
BMC Med Genomics. 2021 Nov 9;14(1):265
pubmed: 34753501
Breast. 2019 Apr;44:1-14
pubmed: 30580169
Cancer Metastasis Rev. 2020 Jun;39(2):435-453
pubmed: 32458269
Nat Commun. 2018 Dec 3;9(1):5137
pubmed: 30510281
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Curr Biol. 2020 Aug 17;30(16):R921-R925
pubmed: 32810447
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Mol Cancer. 2016 Nov 16;15(1):71
pubmed: 27852311
Int J Cancer. 2017 Jan 1;140(1):163-175
pubmed: 27632554
Breast Cancer Res. 2012 Jul 27;14(4):R113
pubmed: 22839103
Breast. 2022 Feb;61:123-128
pubmed: 34995921
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Cell Death Dis. 2020 Apr 9;11(4):228
pubmed: 32273493
Oncol Lett. 2018 Jun;15(6):9271-9282
pubmed: 29805656
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Control Clin Trials. 1998 Dec;19(6):589-601
pubmed: 9875838

Auteurs

Christopher Godina (C)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden.

Vineesh Indira Chandran (V)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden.

Magdalena Barbachowska (M)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden.

Helga Tryggvadottir (H)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Sweden.

Björn Nodin (B)

Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Lund, Sweden.

Edward Visse (E)

Division of Neurosurgery, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Lund, Sweden.

Signe Borgquist (S)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden; Department of Oncology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.

Karin Jirström (K)

Division of Oncology and Therapeutic Pathology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Lund, Sweden.

Karolin Isaksson (K)

Division of Surgery, Department of Clinical Sciences in Lund, Lund University and Kristianstad Hospital, Kristianstad, Sweden.

Ana Bosch (A)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Sweden.

Mattias Belting (M)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Sweden; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

Helena Jernström (H)

Division of Oncology, Department of Clinical Sciences in Lund, Lund University and Skåne University Hospital, Barngatan 4, Lund SE-221 85, Sweden. Electronic address: helena.jernstrom@med.lu.se.

Classifications MeSH